Tiansheng Pharmaceutical Group Co Ltd

Tiansheng Pharmaceutical Group Co Ltd has a debt-to-equity ratio of 0.23, indicating a relatively conservative capital structure. However, the company reported negative net cash after subtracting total debt, signaling potential liquidity constraints. The current ratio of 1.6 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the negative operating income of CNY -23.8 million and net loss of CNY -22.6 million raise concerns about its ability to generate consistent cash flows.

The company's profitability metrics are weak, with a return on equity of -1.1% and a return on assets of -0.81%. These figures fall significantly below the typical performance of firms in the pharmaceutical industry, which is characterized by high R&D investment and long development cycles. The negative operating income and net loss indicate that the company is currently not generating sufficient revenue to cover its operating costs and is not profitable.

Tiansheng Pharmaceutical Group Co Ltd's revenue is concentrated in a single geographic market, China, with no disclosed international operations. The company does not provide segment-level revenue breakdowns, making it difficult to assess the performance of individual product lines or therapeutic areas. This lack of diversification increases the company's exposure to domestic regulatory, economic, and competitive risks.

The company's growth trajectory is uncertain, as it reported a net loss in the most recent period. Historical revenue data is not provided, but the negative operating income and net loss suggest a decline in profitability. The company's capital expenditures of CNY -39.0 million indicate a reduction in investment in new facilities or equipment, which may signal a strategic shift or financial constraints.

The company faces several risk factors, including liquidity concerns due to negative net cash after debt and the potential for dilution, although the risk is currently assessed as low. The negative operating income and net loss suggest that the company may need to raise additional capital in the future, which could lead to share dilution. The company has not disclosed any recent equity offerings or dilutive events, but the risk of future dilution remains.

Recent filings and transcripts do not provide detailed insights into the company's strategic direction or operational performance. The company's 10-K filing does not include a comprehensive discussion of its business strategy, competitive landscape, or future outlook. The lack of detailed disclosures limits the ability to assess the company's long-term prospects and risk profile.

Tiansheng Pharmaceutical Group Co Ltd (002872.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification serves as the most material change in the company's profile, establishing a clear baseline for its operational identity within the broader market taxonomy. Alongside this sectoral definition, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides a foundational view of shareholder equity protection. Conversely, liquidity risk has been classified as medium, suggesting that while the company maintains operational fluidity, there may be moderate constraints or variability in its short-term cash management or market trading depth. This distinction highlights a balanced but cautious outlook on the firm's immediate financial flexibility compared to its long-term equity stability. These updates collectively refine the analytical profile of Tiansheng Pharmaceutical Group, moving from an undefined state to a structured assessment of its sectoral role and risk parameters. The absence of analyst coverage or index membership data in the current snapshot underscores that these changes represent a foundational data establishment rather than a reaction to recent market events or external ratings adjustments.

Net income improved by 36.6% year-over-year, signaling a potential stabilization in profitability trends despite ongoing losses.

Operating income grew 32.8% year-over-year, indicating improved core operational efficiency compared to the prior fiscal period.

The debt-to-equity ratio of 0.23 is below the pharmaceutical cohort median of 0.18, suggesting manageable leverage levels.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Gross profit remained substantial at 298 million CNY in FY-4, maintaining a buffer against operating expenses.

The company faces high credit risk, raising significant concerns about its ability to meet financial obligations.

Free cash flow turned negative to -119.5 million CNY in FY-4, worsening from -48 million CNY in FY-1.

Cash conversion ratio of -0.20 is in the bottom quartile, far below the cohort median of 0.95.